Recurrent Herpes Infection in Two Cases with Chronic Myeloid Leukemia Using Dasatinib
نویسندگان
چکیده
Viral infections especially herpes virus and varicella zoster are common complications in patients with hematologic malignancies. The spectrum of infectious during after dasatinib therapy not known. I report here recurrent labialis two chronic myeloid leukemia cases treated dasatinib.
منابع مشابه
Dasatinib in chronic myeloid leukemia: a review
Deregulated BCR-ABL tyrosine kinase (TK) activity is the molecular marker for chronic myeloid leukemia (CML), which provides an identifiable target for developing therapeutic agents. Imatinib mesylate, a BCR-ABL TK inhibitor, is the frontline therapy for CML. Despite the stunning efficacy of this agent, a small number of patients develop a suboptimal response or resistance to imatinib. In newly...
متن کاملDasatinib-induced chylothorax in chronic myeloid leukemia.
Pulmonary adverse events are common abnormalities associated with the use of dasatinib in chronic myeloid leukemia. We present a case of a 69-year-old man who suddenly developed a rare chylothorax pulmonary adverse event following 10 months of dasatinib treatment.
متن کاملSystematic review of dasatinib in chronic myeloid leukemia
Dasatinib is a dual tyrosine kinase inhibitor active against ABL and Src family kinases, and is approved for the treatment of chronic myeloid leukemia (CML) patients in chronic, accelerated, or blast phase with resistance or intolerance to imatinib therapy, for newly diagnosed chronic phase patients, and for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia who have beco...
متن کاملDasatinib in the treatment of imatinib refractory chronic myeloid leukemia
The development of imatinib for the treatment of chronic myeloid leukemia (CML) has proven to be an example of medical success in the era of targeted therapy. However, imatinib resistance or intolerance occurs in a substantial number of patients. Additionally, patients who have progressed beyond the chronic phase of CML do relatively poorly with imatinib therapy. Mechanisms of imatinib resistan...
متن کاملA once-daily dasatinib dosing strategy for chronic myeloid leukemia.
The BCR-ABL inhibitor imatinib is standard first-line therapy for patients with chronic myeloid leukemia (CML) and has revolutionized treatment of the disease. However, resistance and intolerance to the agent have emerged as major clinical complications. Dasatinib is the first and only dual BCR-ABL/SRC family kinase inhibitor approved by the U.S. Food and Drug Administration for the treatment o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Mu?la S?tk? Koçman üniversitesi t?p dergisi
سال: 2023
ISSN: ['2148-8118', '2618-6020']
DOI: https://doi.org/10.47572/muskutd.1015154